Holzkirchen, October 14, 2015 - Last night in Madrid, Sandoz picked-up three accolades at the Global Generics & Biosimilars Awards hosted by the Generics Bulletin including Company of the Year.
The recent launch of Zarxio, the first US biosimilar, which has paved the way for greater access to high-quality biologics won Biosimilar Initiative of the Year. In September this year, Sandoz became the first company to introduce a biosimilar in the US – leading the way in the US just as it did in Europe nearly 10 years ago.
The FDA approval and launch of Glatopa as the first generic competitor to the leading MS therapy Copaxone won Regulatory Achievement of the Year. The approval and subsequent launch reinforced Sandoz leadership in a field of complex, differentiated generic products. It further demonstrated Sandoz’ commitment to offer patients and payors a full range of therapeutic options.
The awards night culminated in Sandoz being named Company of the Year having met several significant milestone achievements and achieved four quarters of strong growth driven by renewed strategic focus for 2015 and onwards.
Collecting the awards were Carol Lynch, Global Head of Biopharmaceuticals & Oncology Injectables, Mark McCamish, Head of Global Biopharmaceutical & Oncology Injectables Development and Greg Oakes, Vice President and Head, Biopharmaceuticals, North America and Sreejit Mohan, Global Head, Franchise Communications.
From left to right: Greg Oakes, Mark McCamish, Carol Lynch and Sreejit Mohan